Viyash Scientific Ltd Upgraded to Hold on Technical and Financial Improvements

Technical Trends Signal Mild Bullish Momentum

The primary catalyst for the upgrade lies in the technical assessment of Viyash Scientific’s stock. The technical trend has shifted from a sideways pattern to a mildly bullish stance, supported by several key indicators. Daily moving averages have turned bullish, suggesting positive short-term momentum. Additionally, Bollinger Bands on both weekly and monthly charts indicate bullish conditions, reinforcing the upward price movement.

However, the technical picture remains mixed. The weekly MACD is mildly bearish, while the monthly MACD is bullish, reflecting some divergence in momentum across timeframes. The KST indicator remains bearish on a weekly basis and mildly bearish monthly, and Dow Theory assessments also show mild bearishness. The On-Balance Volume (OBV) is mildly bearish weekly but shows no clear trend monthly. Relative Strength Index (RSI) readings on both weekly and monthly charts do not currently signal overbought or oversold conditions, indicating a neutral momentum backdrop.

Overall, the technical upgrade to a mildly bullish trend supports a Hold rating, as the stock demonstrates potential for further gains but with caution warranted due to mixed signals.

Robust Financial Performance Bolsters Confidence

Viyash Scientific’s financial trend has markedly improved, particularly highlighted by its outstanding Q3 FY25-26 results. The company reported a remarkable 78.2% growth in operating profit for the quarter ended December 2025, continuing a streak of positive results over the last eight consecutive quarters. This consistent profitability underscores operational strength and effective cost management.

Return on Capital Employed (ROCE) for the half-year period reached a high of 18.65%, a significant improvement over the company’s long-term average ROCE of 7.40%. This indicates enhanced capital efficiency and better utilisation of resources. The operating profit to interest ratio stands at an impressive 10.49 times, reflecting strong debt servicing capability. Furthermore, the debt-to-equity ratio has decreased to a low 0.61 times, signalling a conservative capital structure and reduced financial risk.

Promoter confidence has also surged, with promoters increasing their stake by 9.1% over the previous quarter to hold 61.43% of the company. This substantial insider buying is often interpreted as a positive signal regarding the company’s future prospects.

Valuation Reflects Premium but Discount to Peers

Despite the strong recent performance, Viyash Scientific’s valuation remains somewhat expensive on certain metrics. The company’s ROCE of 18.1% corresponds with an enterprise value to capital employed ratio of 7.8, indicating a premium valuation relative to its capital base. However, when compared to peers within the Pharmaceuticals & Biotechnology sector, the stock trades at a discount to average historical valuations, suggesting some relative value remains.

Over the past year, the stock price has surged by 53.45%, outpacing the BSE500 index and delivering substantial returns to shareholders. Profit growth has been even more pronounced, with profits rising by 138.8% in the same period. This results in a PEG ratio of 1.7, which, while above 1, suggests that the stock’s price growth is somewhat aligned with its earnings expansion, though not excessively undervalued.

Long-term sales and operating profit growth rates have been moderate, with net sales growing at an annualised 14.17% and operating profit at 12.25% over the last five years. These figures indicate steady but unspectacular expansion, which tempers the valuation premium.

Quality Assessment: Mixed Signals from Long-Term Fundamentals

While recent quarters have demonstrated outstanding financial results, the company’s long-term fundamental quality remains mixed. The average ROCE over the longer term is a modest 7.40%, which is below industry-leading standards. Additionally, the company’s ability to service debt is somewhat constrained, with a debt to EBITDA ratio of 1.32 times, indicating moderate leverage risk.

Nevertheless, the company’s consistent positive quarterly results and improving capital efficiency suggest that quality is on an upward trajectory. The rising promoter stake further reinforces confidence in the company’s governance and strategic direction.

Stock Performance Relative to Market Benchmarks

Viyash Scientific has delivered strong returns relative to the Sensex and broader market indices. Over the last week, the stock gained 8.75%, outperforming the Sensex’s 6.06% rise. The one-month return of 3.45% contrasts favourably with the Sensex’s decline of 1.72%. Year-to-date, the stock is up 0.89%, while the Sensex has fallen by 8.99%. Over the last year, the stock’s 53.45% return dwarfs the Sensex’s 4.49% gain, and over three years, the stock has surged 180.71% compared to the Sensex’s 29.63%.

However, over a five-year horizon, the stock has underperformed with a negative return of 21.92%, while the Sensex gained 55.92%. Over ten years, the stock’s 25.90% return trails the Sensex’s 214.35% gain. This mixed long-term performance highlights the importance of recent improvements in financial and technical metrics for the upgrade decision.

Conclusion: A Cautious Hold with Potential Upside

The upgrade of Viyash Scientific Ltd’s investment rating from Sell to Hold reflects a balanced view of the company’s current standing. The technical indicators have improved to a mildly bullish trend, signalling positive momentum. Financially, the company has demonstrated outstanding recent performance with strong operating profit growth, improved capital efficiency, and reduced leverage, supported by increased promoter confidence.

Valuation remains somewhat elevated but is justified by robust profit growth and relative discount to peers. Long-term fundamental quality is mixed, with moderate historical returns and growth rates, but recent trends suggest improvement. The stock’s performance relative to market benchmarks has been strong in the short to medium term, though long-term returns have been less impressive.

Investors are advised to maintain a Hold stance, recognising the company’s improving fundamentals and technical outlook while remaining mindful of valuation and long-term growth challenges. This rating reflects a cautious optimism that Viyash Scientific can sustain its recent momentum and deliver value over the coming quarters.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →